NASDAQFinancialsInsurance - SpecialtySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TIPT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successful integration of Fortegra acquisition | A primary condition in Tiptree, Inc.'s published investment case. The stated target is complete integration and synergy realization by end 2026. | Improving | acquisition integration delays or failures reported in 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
TIPT is a financial company with a specialty-insurance growth angle and capital returned through repurchases and a dividend. Its long-term thesis remains in a watch state because recent financial performance is weak, despite robust earnings quality and a moderate risk label.
The valuation evidence describes TIPT as cheap versus peers, while the expectations gap is negative, suggesting the market’s expectations may be demanding relative to the model’s view. The pricing assessment is tagged justified, and the evidence shows low fragility, so it does not point to concentrated pricing risk.
Near term, erratic earnings surprises and recent peer misses make the next results worth watching; the snapshot puts the miss probability at 45%. Management has announced a proposed USIG acquisition, but the supplied financials do not yet show results from it, while recent operating results were weak. Repurchases and the repeated dividend declaration show delivery on capital-return commitments.
A guidance cut at the next call would be a meaningful negative, while continued earnings strength and higher guidance from sector peers could support the sector backdrop. The rate scenario is also important: the evidence says financial companies tend to fare better when rates stay high, so rate cuts could weigh on TIPT. Over the multi-year view, execution on the specialty-insurance acquisition remains an important test.
TIPT’s long-term thesis combines a peer-cheap valuation and demonstrated capital returns with weak recent performance and limited evidence yet of acquisition results. The 1-3 year view hinges on guidance, sector conditions, and management execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company maintains a steady dividend of $0.06 per share. |
| Intact |
| dividend per share falls below $0.06 in next 4 quarters |
Dividend per share: $0.06 per share FY2026-Q3; GAAP. Published target: >=0.06 USD per share. Target period is not explicitly aligned with this observation. Oct 28, 20260.06 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 3 supplied quarters. Management reported: “• Declared a dividend of $0.06 per share to stockholders of record on November 16, 2026 with a payment date of November 23, 2026.” “• Declared a dividend of $0.06 per share to stockholders of record on August 17, 2026 with a payment date of August 24, 2026.” Delivery assessment Nov 4, 2026 |
Revenue above $540 million in 2025 | Revenue is expected above $540 million in 2025. | Intact | revenue falls below $540 million in FY25 | Revenue: $11.052M FY2026-Q3; GAAP. Published target: >=540.3 USD_MILLIONS. Annual target cannot be compared with a quarterly or TTM observation. Oct 28, 202611,052,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain valuation discount to peers | Its valuation is cheap compared to peers with a P/E of 12.8 versus 15.3. | Intact | P/E rises above 15 without earnings growth | P/E (TTM): 21.25x As of 2026-11-04; trailing twelve months. The target timing and basis require a separate assessment. Nov 4, 202621.2501 ratio · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.